Moderna (MRNA)
(Delayed Data from NSDQ)
$86.84 USD
+0.22 (0.25%)
Updated Aug 16, 2024 03:55 PM ET
After-Market: $86.91 +0.07 (0.08%) 5:30 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.84 USD
+0.22 (0.25%)
Updated Aug 16, 2024 03:55 PM ET
After-Market: $86.91 +0.07 (0.08%) 5:30 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
Zacks News
Oxford Industries and Flagstar Bancorp have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Oxford Industries and Flagstar Bancorp have been highlighted as Zacks Bull and Bear of the Day.
FDA Panel Recommends Pfizer & Moderna COVID Jabs for Young Kids
by Kinjel Shah
The FDA VRBPAC committee unanimously recommends the approval of both Pfizer and BioNTech and Moderna's vaccines for young children, saying the benefits of the vaccines outweigh the risks.
Pfizer (PFE) Starts EU Submission of Variant-Adapted Vaccine
by Zacks Equity Research
Pfizer (PFE) and its partner BioNTech initiate rolling submission, seeking authorization of the variant-adapted version of their COVID-19 vaccine.
Moderna's (MRNA) COVID-19 Vaccine Nears EUA in Pediatrics
by Zacks Equity Research
An FDA advisory committee voted in favor of the use of Moderna's (MRNA) COVID-19 vaccine in individuals aged 6 years to 17 years. A meeting to discuss the use of the vaccine in the younger population is scheduled for today.
Pfizer, BioNTech's COVID Jab Safe in Young Kids Per FDA
by Zacks Equity Research
Per the FDA reviewers, the available data supports Pfizer (PFE) and BioNTech (BNTX) vaccine's effectiveness in preventing COVID infection in kids six months to under five years of age as a three-dose primary series.
Moderna's (MRNA) Omicron-Specific Booster Jab Meets Study Goal
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID booster candidate targeting the Omicron variant achieved all pre-specified endpoints in a phase II/III study.
Why Is Exelixis (EXEL) Down 3.1% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News for Jun 9, 2022
by Zacks Equity Research
Companies in The News Are: THO,CPB,MRNA,INTC
FDA Committee Proposes EUA Nod to Novavax's (NVAX) COVID Jab
by Zacks Equity Research
An FDA advisory committee supports granting emergency use authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. Post the news, the stock rallies 20% in pre-market trading.
Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
Novavax (NVAX) Down After FDA Raises Concern for Its COVID Jab
by Zacks Equity Research
Before deciding the fate of Novavax's (NVAX) COVID-19 vaccine, a document issued by the FDA suggests that the vaccine may cause heart problems like myocarditis/pericarditis.
Why Is Moderna (MRNA) Down 1.3% Since Last Earnings Report?
by Zacks Equity Research
Moderna (MRNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer (PFE) Leads as US Plans Kids' COVID Vaccination in June
by Zacks Equity Research
The FDA accepts the EUA request from Pfizer (PFE) for its COVID-19 vaccine for use in kids below 5 years of age. The U.S. government plans to start vaccinating these kids in June, following an FDA panel advisory.
AstraZeneca (AZN) Gets EU Nod for COVID-19 Booster Shot
by Zacks Equity Research
AstraZeneca's (AZN) third/booster dose of its COVID-19 vaccine gets authorized in Europe for use in adults, both for homologous and heterologous use.
Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA
by Zacks Equity Research
Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).
Pfizer & BioNTech COVID Jab Booster Effective in Kids Under 5
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) state that their three-dose COVID-19 vaccine is 80% effective in children under five years of age.
Moderna (MRNA) Stock Rises 4%: What's Behind the Upside?
by Zacks Equity Research
Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.
Pfizer (PFE) Gets EUA for Use of Comirnaty Booster in Children
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech gets authorization for emergency use of booster dose of its COVID-19 vaccine, Comirnaty, in children aged between 5 years and 11 years.
Vertex (VRTX) Outperforms Industry This Year So Far: Here's Why
by Zacks Equity Research
Vertex's (VRTX) cystic franchise sales continue to grow. Vertex has a broad clinical non-CF pipeline, which is progressing rapidly.
Company News for May 12, 2022
by Zacks Equity Research
Companies in The News Are: MRNA, COIN, OXY, SWCH, DBRG
Novavax (NVAX) Down on Q1 Earnings and Sales Lagging Estimates
by Zacks Equity Research
Novavax (NVAX) misses on both earnings and sales for the first quarter of 2022. Its shares decline in after-hours trading following the result announcement.
J&J (JNJ) Updates COVID Jab Label to Include Blood Clot Risk
by Zacks Equity Research
J&J's (JNJ) decision to update the label of its COVID-19 vaccine came on the heels of the FDA's decision to limit the authorized use of its vaccine due to the risk of TTS.
Moderna (MRNA) Beats on Q1 Earnings, to Start Two Late Studies
by Zacks Equity Research
Moderna's (MRNA) Spikevax sales beat expectations. The company plans to start late-stage studies for Omicron-containing bivalent booster and seasonal flu vaccines later this year. Stock gains in pre-market.
Moderna (MRNA) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 65.64% and 34.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat Likely for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the first-quarter earnings call that can help it to reduce its dependence on Spikevax.